CROSS-STANDARD public interest · Home/clinical medical device

China-to-UK Medical Device Compliance Gap Matrix

AI-compiled from official public sources — cross-checked by multiple AI models, not human-verified. Informational only; see disclaimer. Public-interest, source-linked comparison of common China home and clinical medical device documentation against UK Medical Devices Regulations 2002 (SI 2002/618) conformity, UKCA marking, UK Approved Body, MHRA registration, UK Responsible Person, ISO 13485, BS EN 60601-1 electrical safety, IEC 62304 software, and clinical evaluation expectations.

Dataset 2026-06-11 Last verified 2026-06-12 8 rows

GAP MATRIX

Compliance Gap Matrix

Gap matrix
Compliance item Common China baseline United Kingdom (UKCA / MHRA) Gap / action Source + verification date
UK Medical Device Classification — UKCA / MHRA Rules NMPA classifies medical devices under the 2021 Administrative Measures (Order No. 47) into Class I (low risk, provincial filing), Class II (medium risk, provincial NMPA registration), and Class III (high risk, national NMPA full review). Classification is determined by the NMPA Classification Catalogue (Announcement No. 104/2017 and amendments through Announcement No. 132/2025). The classification logic and risk-tier assignments do not map directly to UK classes; the same physical device may receive a different class in each system.NMPA Order No. 47 (2021) — Administrative Measures for Medical Device Registration and Filing
State Council Order No. 739 — Regulations on the Supervision and Administration of Medical Devices (2021)
NMPA Classification Catalogue (Announcement No. 104/2017 + amendments to No. 132/2025)		 The UK Medical Devices Regulations 2002 (SI 2002/618), as amended — most recently by the Medical Devices (Amendment) (Great Britain) Regulations 2024 and the Medical Devices (Post-market Surveillance and Miscellaneous Amendments) Regulations 2024 — govern device classification in Great Britain (England, Scotland, Wales). Classification rules for general medical devices mirror EU MDD Annex IX rules (not MDR Annex VIII rules), applying Classes I, IIa, IIb, and III based on intended use, duration, invasiveness, and body interaction. Northern Ireland follows a different route (see note on UKNI/CE). Class I devices are generally self-certified; Class IIa, IIb, and III require a UK Approved Body (formerly Notified Body) for conformity assessment. MHRA is the competent authority. Note: The UK Government has announced a new UK MDR framework (expected to come into force 2025–2026 in phased implementation); manufacturers should monitor MHRA guidance for the precise transition timeline as the new rules may align more closely with EU MDR 2017/745 classification logic.UK Medical Devices Regulations 2002 (SI 2002/618) as amended — Schedule 7 (classification rules for general medical devices)
Medical Devices (Amendment) (Great Britain) Regulations 2024
Medical Devices (Post-market Surveillance and Miscellaneous Amendments) Regulations 2024
MHRA Guidance: Classification of medical devices (gov.uk)
MHRA: New UK MDR Framework — Implementation Road Map (gov.uk)		 UK classification rules are currently based on EU MDD Annex IX (not MDR Annex VIII); a device classified under NMPA cannot be assumed to fall into the same UK class. Key gaps: (1) Manufacturers must re-apply classification rules under SI 2002/618 Schedule 7 independently of NMPA class; (2) UK Approved Body engagement is required for Class IIa/IIb/III — no NMPA equivalent; (3) A new UK MDR framework is expected in 2025–2026 that may bring classification rules closer to EU MDR Annex VIII — transition timelines are uncertain; (4) Northern Ireland CE/CE-UKNI route differs from Great Britain UKCA route; (5) MHRA registration on the MHRA Device Registration System (DORS) is required separately.[INFORMATIONAL ONLY] Manufacturers must independently determine UK device class under SI 2002/618 Schedule 7 — NMPA classification cannot be transposed directly. Engage an MHRA-listed UK Approved Body early for Class IIa and above. Monitor MHRA guidance for the new UK MDR framework transition dates. This is informational; seek qualified UK regulatory counsel before placing devices on the Great Britain market. MHRA / UK Government (gov.uk)2026-06-12 · unverified
UKCA Marking and CE / CE-UKNI Transitional Acceptance NMPA registration or filing (NMPA Certificate or Filing Receipt) is the equivalent market authorisation for the Chinese domestic market. There is no UKCA-equivalent mark in China; conformity is demonstrated through NMPA registration documents, not a mark affixed to the device. NMPA registration does not confer any recognition in the UK.NMPA Order No. 47 (2021) — Administrative Measures for Medical Device Registration and Filing
State Council Order No. 739 — Regulations on the Supervision and Administration of Medical Devices (2021)		 UKCA (UK Conformity Assessed) marking is the mandatory conformity mark for medical devices placed on the Great Britain market. For devices manufactured outside the UK, UKCA marking requires conformity assessment by a UK Approved Body for Class IIa, IIb, and III devices. Class I general devices may self-certify via a UK Declaration of Conformity. Transitional provisions (MHRA confirmed categories as of June 2026): (1) MDD/AIMDD general devices — CE certificates accepted on the GB market until the sooner of certificate expiry or 30 June 2028; (2) IVDD in-vitro diagnostic devices — CE certificates accepted until 30 June 2030; (3) EU MDR 2017/745 and EU IVDR 2017/746 certificates — accepted until 30 June 2030; (4) Class I devices self-declared under MDD/AIMDD — accepted on the GB market under MHRA conditions (not a blanket 2030 date — manufacturers must meet MHRA-specified conditions). All transitional routes require MHRA DORS registration and a UK Responsible Person. These dates and conditions are subject to MHRA revision; verify against current MHRA guidance before planning market entry. Northern Ireland: CE or CE-UKNI marking is required (not UKCA); CE-UKNI marking applies to devices covered by EU MDR via the Windsor Framework.UK Medical Devices Regulations 2002 (SI 2002/618) as amended — UKCA marking obligations
MHRA Guidance: Placing medical devices on the market in Great Britain — UKCA marking (gov.uk, updated 2024–2026)
MHRA Transitional Arrangements for CE-marked devices in Great Britain (gov.uk)
Windsor Framework (Northern Ireland Protocol successor) — CE/CE-UKNI in Northern Ireland		 NMPA registration provides no recognition in the UK. Key gaps: (1) UKCA marking must be obtained independently; for non-UK manufacturers this requires a UK Approved Body for Class IIa+; (2) CE transitional acceptance is time-limited and certificate-type-dependent — MDD/AIMDD general devices accepted until sooner of certificate expiry or 30 June 2028; IVDD until 30 June 2030; EU MDR/EU IVDR certificates until 30 June 2030; Class I MDD self-declared under MHRA conditions only — do not assume a blanket 2030 cut-off; all dates subject to MHRA revision; (3) Manufacturers must register with MHRA on DORS before placing devices on the UK market, regardless of CE or UKCA route; (4) A UK Responsible Person (UKRP) is mandatory for non-UK manufacturers — a legal entity or individual established in the UK who registers the device with MHRA on behalf of the manufacturer; (5) Northern Ireland requires CE or CE-UKNI marking, not UKCA.[INFORMATIONAL ONLY] Chinese manufacturers must obtain UKCA marking (or rely on CE transitional acceptance before its expiry) and appoint a UK Responsible Person before placing devices on the Great Britain market. CE transitional cut-offs differ by certificate type: MDD/AIMDD general devices — sooner of certificate expiry or 30 June 2028; IVDD — 30 June 2030; EU MDR/IVDR — 30 June 2030; Class I MDD self-declared — MHRA conditions apply, not a blanket 2030 date. All dates subject to MHRA revision — do not plan market entry based solely on current published dates. This is informational; seek qualified UK regulatory counsel. MHRA / UK Government (gov.uk)2026-06-12 · unverified
Clinical Evaluation and Performance Evidence under UK MDR NMPA requires clinical evidence for Class II and Class III medical device registration under Order No. 47 (2021). Clinical evaluation routes include: clinical trials conducted in China to NMPA Good Clinical Practice (GCP) requirements, clinical literature review and clinical data analysis, or reliance on equivalent device data. NMPA published specific technical guidelines for clinical evaluation of medical devices (2021 and subsequent updates). Clinical trials for Class III high-risk devices typically require NMPA-approved trials conducted at designated Chinese clinical sites. Foreign clinical data may be accepted for certain device types under specific conditions. Post-market surveillance obligations exist under NMPA regulations but are generally less prescriptive than UK/EU PMCF obligations. Risk management per YY/T 0316-2016 (ISO 14971:2007 aligned) is required; NMPA is transitioning to ISO 14971:2019 aligned requirements.NMPA Order No. 47 (2021) — Administrative Measures for Medical Device Registration and Filing (clinical evidence requirements)
NMPA Clinical Evaluation Technical Guidelines for Medical Devices (2021 and amendments)
YY/T 0316-2016 — Medical devices — Application of risk management to medical devices (aligned to ISO 14971:2007)
ISO 14971:2019 — adoption underway by NMPA		 The UK Medical Devices Regulations 2002 (SI 2002/618), Schedule 1 Essential Requirements, require manufacturers to demonstrate that devices achieve the intended performance and that risks are acceptable in relation to benefit. Clinical evaluation — a systematic and planned process to continuously generate, collect, analyse, and assess clinical data — is the primary route to fulfil clinical-evidence Essential Requirements for Class IIa, IIb, and III devices. The methodology follows ISO 14155:2020 (Clinical investigation of medical devices for human subjects) and is expected to align with MHRA guidance on clinical evaluation. Clinical data sources include: clinical investigations, clinical literature review, and post-market clinical follow-up (PMCF). Equivalent device equivalence claims must be rigorously justified with technical, biological, and clinical equivalence demonstrated. Post-market surveillance (PMS) and PMCF are mandatory ongoing obligations under SI 2002/618 and MHRA guidance. Risk management per ISO 14971:2019 must be integrated with clinical evaluation findings. The new UK MDR framework (expected 2025–2026) is likely to introduce more prescriptive clinical evidence requirements aligned with EU MDR Annex XIV.UK Medical Devices Regulations 2002 (SI 2002/618) — Schedule 1, Essential Requirements (clinical evidence obligations)
ISO 14155:2020 — Clinical investigation of medical devices for human subjects — Good clinical practice
ISO 14971:2019 — Medical devices — Application of risk management to medical devices
MHRA Guidance: Clinical investigations and clinical performance studies for medical devices and IVDs (gov.uk)
MHRA Guidance: Post-market surveillance for medical devices (gov.uk)		 Both systems require clinical evidence, but the structure and rigor differ. Key gaps: (1) NMPA clinical trial data from Chinese sites does not automatically satisfy UK clinical evaluation requirements — UK technical file must contain a clinical evaluation report (CER) structured to SI 2002/618 and MHRA guidance; (2) Equivalence claims require documented technical, biological, and clinical equivalence with access to the equivalent device manufacturer's technical documentation — NMPA equivalence routes are less prescriptive; (3) UK PMCF obligations require ongoing data collection plans and periodic safety update reports (PSURs) per MHRA guidance — NMPA post-market obligations are less detailed; (4) Risk management must be updated to reference ISO 14971:2019 and integrated with the UK clinical evaluation; (5) The forthcoming new UK MDR framework may require a dedicated Summary of Safety and Clinical Performance (SSCP) similar to EU MDR Annex XV.[INFORMATIONAL ONLY] NMPA clinical data provides a starting point but a UK-structured Clinical Evaluation Report (CER) referencing SI 2002/618 and MHRA guidance must be produced independently. Establish a UK PMCF plan and PSUR schedule. Update risk management to ISO 14971:2019. This is informational; seek qualified UK regulatory counsel before submission. MHRA / UK Government (gov.uk)2026-06-12 · unverified
Labelling, Language Requirements, and UDI under UK MDR Chinese medical device labelling is governed by the NMPA Medical Device Labelling and Instructions for Use Regulations (Order No. 6, 2021, as amended). All labelling and IFU must be in Simplified Chinese. Key mandatory elements include: manufacturer name and address; domestic agent name and address; device name; product standard; intended use; batch/lot or serial number; production date; expiry date (if applicable); sterility indication; single-use indication; NMPA registration certificate number. Graphic symbols per GB/T 18268 (aligned to ISO 15223) may be used. Chinese UDI: NMPA has implemented a UDI system (National Medical Device Unique Identification Database — NMPA UDI Database); Class III devices required UDI from 2021; Class II from 2023; Class I from 2025 (phased schedule — verify current NMPA guidance for completeness).NMPA Order No. 6 (2021) — Regulations on Medical Device Labelling and Instructions for Use (as amended)
GB/T 18268 series — Symbols used in medical device labelling (aligned to ISO 15223)
NMPA UDI Implementation Regulations and Phased Schedule (2021–2025)		 The UK Medical Devices Regulations 2002 (SI 2002/618), Schedule 1 (Essential Requirements) and Schedule 2, set mandatory labelling requirements for medical devices placed on the Great Britain market. All labelling and instructions for use (IFU) must be in English. Key mandatory label elements include: manufacturer name and address; device name or trade name; intended purpose; lot/batch number or serial number; expiry date (if applicable); sterile indication (if applicable); single-use indication (if applicable); UKCA mark (or CE mark under transitional arrangements); MR safety information (for devices used near MRI). The UKCA mark must be affixed to the device or its packaging (not the IFU alone) for Class IIa and above. Instructions for use must accompany all devices unless MHRA grants an exception for Class I non-sterile, non-measuring devices. UKRP labelling obligation: the UK Responsible Person (UKRP) name, registered address, and contact information must appear on the labelling, packaging, or IFU where the device bears the UKCA mark. This obligation does NOT apply to CE-only transitional devices where no UKCA mark is affixed — unless the device simultaneously bears both CE and UKCA marks, in which case UKRP details are required. For Unique Device Identification (UDI): the UK UDI system is being developed by MHRA under the new UK MDR framework. As of June 2026, full UDI obligations have not yet been mandated under the legacy SI 2002/618, but MHRA has indicated UDI requirements will be introduced as part of the new framework. Manufacturers with existing EU MDR UDI compliance should maintain those systems for future UK UDI applicability.UK Medical Devices Regulations 2002 (SI 2002/618) — Schedule 1 (Essential Requirements), Schedule 2 (labelling and IFU requirements)
MHRA Guidance: Labelling requirements for medical devices (gov.uk)
MHRA Guidance: Unique Device Identification — UK UDI system development (gov.uk)
Medical Devices (Amendment) (Great Britain) Regulations 2024 — UKRP label obligations		 Labelling must be substantially revised for the UK market. Key gaps: (1) Language: all UK labelling and IFU must be in English — Chinese-only labelling is not permissible; (2) UKRP details on labelling: required only where the device bears the UKCA mark (on label, packaging, or IFU); NOT required for CE-only transitional devices unless the device simultaneously bears both CE and UKCA marks — manufacturers relying solely on CE transitional acceptance need not add UKRP to the physical label, but must still register UKRP with MHRA on DORS; (3) UKCA mark (or CE under transitional arrangements) must replace or supplement NMPA/Chinese-market-only marks; (4) UK UDI obligations are not yet fully mandated under the current SI 2002/618 but will be required under the new UK MDR framework — manufacturers with EU MDR UDI compliance have a head start; Chinese NMPA UDI registration does not transfer to the UK UDI database; (5) Graphic symbols: BS EN ISO 15223 (identical to ISO 15223) symbols are recognised in the UK — manufacturers can align labels to use internationally harmonised symbols to reduce re-labelling burden.[INFORMATIONAL ONLY] Chinese-market labelling requires substantial revision for the UK: English translation of all text, UKCA mark (or CE under transitional acceptance), and preparation for forthcoming UK UDI obligations. UKRP details (name, registered address, contact) must appear on labelling/packaging/IFU only where the device carries the UKCA mark — manufacturers relying solely on CE transitional acceptance are NOT required to add UKRP to the physical label, though UKRP registration with MHRA on DORS remains mandatory regardless of marking route. Design label changes early as they affect production runs and DORS registration data. This is informational; seek qualified UK regulatory counsel. MHRA / UK Government (gov.uk)2026-06-12 · unverified
Quality Management System — ISO 13485 under UK MDR China requires ISO 13485-aligned QMS for Class II and III medical device manufacturers under NMPA Order No. 47 (2021) and the Medical Device Production Quality Management Specification (GMP, NMPA Order No. 107, issued November 2025, effective November 2026, superseding Order No. 64). YY/T 0287-2017 (identical to ISO 13485:2016) is the Chinese industry standard. NMPA conducts on-site GMP inspections for Class II and III manufacturers; foreign manufacturers exporting to China must also pass NMPA overseas inspection or provide equivalent quality system documentation. ISO 13485 certificates from CNAS-accredited certification bodies are accepted. The QMS scope, document control, and CAPA requirements are substantively similar to UK expectations.YY/T 0287-2017 — Medical devices — Quality management systems — Requirements for regulatory purposes (identical to ISO 13485:2016)
NMPA Order No. 47 (2021) — Administrative Measures for Medical Device Registration and Filing
NMPA Order No. 107 (2025) — Medical Device Production Quality Management Specification (GMP, effective November 2026)
NMPA Order No. 64 (superseded by Order No. 107 from November 2026)		 The UK Medical Devices Regulations 2002 (SI 2002/618) require manufacturers of Class IIa, IIb, and III devices to implement and maintain a Quality Management System (QMS) as part of conformity assessment. ISO 13485:2016 (Medical devices — Quality management systems — Requirements for regulatory purposes) is the internationally accepted standard and is required in practice by UK Approved Bodies for all Class IIa+ conformity assessment routes. A UK Approved Body assesses the QMS as part of a full quality assurance annex assessment or a production quality assurance module. The QMS must cover design and development (for Class IIb/III), production, post-market surveillance, complaint handling, CAPA, and regulatory reporting. ISO 13485 certification from a UKAS-accredited (or equivalent) certification body is strongly expected, though the Approved Body conducts its own audit. For Class I devices, a QMS is not assessed by an Approved Body but a documented system is good regulatory practice and will be expected under the new UK MDR framework.UK Medical Devices Regulations 2002 (SI 2002/618) — Schedule 3 (Full Quality Assurance), Schedule 4 (EC Type-examination equivalent), Schedule 5 (Production Quality Assurance)
ISO 13485:2016 — Medical devices — Quality management systems — Requirements for regulatory purposes
MHRA Guidance: Conformity assessment routes for medical devices (gov.uk)		 The substantive QMS requirements under ISO 13485:2016 are the same for both UK and CN markets. Key gaps: (1) UK requires assessment by a MHRA-listed UK Approved Body (not NMPA or any Chinese body); existing ISO 13485 certificates from CNAS-accredited bodies may support the application but cannot substitute for the UK Approved Body audit; (2) UK QMS audit scope must cover UK-specific regulatory obligations (post-market surveillance reporting to MHRA, UK Serious Adverse Event reporting timelines, UK vigilance procedures); (3) UK QMS documentation must reference SI 2002/618 and MHRA guidance, not NMPA regulations; (4) Under the forthcoming new UK MDR framework, QMS obligations are expected to align more closely with EU MDR Annex IX requirements, potentially increasing documentation depth for Class IIb/III.[INFORMATIONAL ONLY] An existing ISO 13485:2016 certificate (from a CNAS or equivalent accredited body) provides a solid QMS foundation for UK market entry but must be supplemented by a UK Approved Body audit with UK-specific scope. Update QMS documentation to reference UK regulations and MHRA guidance. This is informational; seek qualified UK regulatory counsel. MHRA / UK Government (gov.uk)2026-06-12 · unverified
Electrical Safety — BS EN 60601-1 under UK MDR GB 9706.1-2020 is China's mandatory national standard for general requirements for basic safety and essential performance of medical electrical equipment, aligned to IEC 60601-1 Ed.3 with minor Chinese deviations. Mandatory for new NMPA registrations from 2023-05-01. Testing must be performed by a CNAS-accredited or NMPA-designated laboratory. Both GB 9706.1-2020 and BS EN 60601-1 derive from the IEC 60601-1 Ed.3 family, so physical test parameters (leakage current, dielectric withstand, insulation) overlap substantially. However, a GB 9706.1-2020 Chinese test report alone does not establish UK presumption of conformity under the designated-standard route; UK technical documentation should reference evidence mapped to BS EN 60601-1:2006+A2:2021 where that route is used.GB 9706.1-2020 — Medical electrical equipment — Part 1: General requirements for basic safety and essential performance (aligned to IEC 60601-1 Ed.3, mandatory from 2023-05-01)
NMPA Medical Device Registration Regulations (Order No. 47, 2021)		 BS EN 60601-1:2006+A2:2021 (consolidated +A13:2024) is a UK designated standard route for general electrical safety of medical electrical equipment under the UK Medical Devices Regulations 2002 (SI 2002/618). The British Standards Institution (BSI) publishes BS EN versions of EN 60601-1. Use of a designated standard is voluntary, but conformity to an applicable standard listed by MHRA gives a presumption of conformity with the relevant Essential Requirements of the UK MDR. UK Approved Bodies may assess electrical safety evidence as part of technical documentation review for Class IIa+ devices. Applicable collateral and particular standards (including the BS EN 60601-2-x series) should be considered for specific device types. Test evidence is normally expected from a UKAS-accredited (or equivalent) ISO 17025 laboratory. The UK designated standards list is published and updated by MHRA / BSI; manufacturers should verify the current list before submission.BS EN 60601-1:2006+A2:2021 (consolidated +A13:2024) — Medical electrical equipment — Part 1: General requirements for basic safety and essential performance (UK designated standard under SI 2002/618; voluntary presumption route)
BS EN 60601-2-x particular standards series (device-type specific, designated where applicable)
UK Medical Devices Regulations 2002 (SI 2002/618) — Schedule 1, Essential Requirements
MHRA: List of designated standards for medical devices (gov.uk, updated periodically)		 Both BS EN 60601-1:2006+A2:2021 and GB 9706.1-2020 derive from the IEC 60601-1 Ed.3 family, providing strong test-data overlap. Key gaps: (1) UK use of BS EN 60601-1 as a designated standard under SI 2002/618 is voluntary but, when used, supports a presumption of conformity with relevant Essential Requirements; a Chinese GB 9706.1 report alone is insufficient for that presumption; (2) UK technical documentation must link electrical safety evidence to the Essential Requirements in SI 2002/618 Schedule 1, not the NMPA GSPR equivalent; (3) Applicable BS EN 60601-2-x particular standards may differ slightly from Chinese YY/T equivalents in test levels or scope; (4) UK Approved Body review is required for Class IIa+ — NMPA-designated testing institutes have no UK recognition; (5) MHRA registration (DORS) and UK Responsible Person obligations apply regardless of electrical safety standard compliance.[INFORMATIONAL ONLY] A device already tested to GB 9706.1-2020 (IEC 60601-1 Ed.3 aligned) has substantial test-data portability to BS EN 60601-1:2006+A2:2021 given the common IEC parentage. To rely on the UK designated-standard presumption route, the UK technical file should include evidence mapped to BS EN 60601-1:2006+A2:2021, normally supported by reports from a UKAS-accredited (or equivalent ISO 17025) laboratory. This is informational; seek qualified UK regulatory counsel before submission. MHRA / UK Government (gov.uk)2026-06-12 · unverified
Software as a Medical Device — IEC 62304 under UK MDR YY/T 0664-2020 is China's industry standard for medical device software lifecycle processes, aligned to IEC 62304:2006+AMD1:2015. It is required for NMPA registration of devices with software components. Software safety classification (A/B/C) and lifecycle documentation requirements are substantively the same as IEC 62304. NMPA additionally published specific technical review guidelines for medical device software (NMPA 2022 guidance) and standalone SaMD registration requirements. GB 9706.1-2020 Clause 14 covers PEMS requirements aligned to IEC 60601-1 Clause 14. The technical content of Chinese software requirements is closely aligned to international standards.YY/T 0664-2020 — Medical device software — Software life cycle processes (aligned to IEC 62304:2006+AMD1:2015)
NMPA Technical Review Guidelines for Medical Device Software (2022)
GB 9706.1-2020 Clause 14 — Programmable electrical medical systems (PEMS)		 IEC 62304:2006+AMD1:2015 (Medical device software — Software life cycle processes) is the internationally accepted standard and the primary UK designated standard for software safety classification and lifecycle management in medical devices under SI 2002/618. Devices with embedded software (including electromedical equipment with control, diagnostic, or therapeutic software) must classify software safety per IEC 62304 Classes A, B, or C based on severity of harm if software fails. Class C (most severe) requires the most rigorous documentation including software requirements specification, software architecture, detailed design, unit testing, integration testing, and system testing. Software of Unknown Provenance (SOUP) must be identified and managed. IEC 62304 is applied alongside IEC 60601-1 Clause 14 (for electromedical equipment) and ISO 14971 (risk management). MHRA publishes guidance on Software as a Medical Device (SaMD) classification and the DCB0129/0160 clinical safety standards apply to health IT systems used in NHS settings.IEC 62304:2006+AMD1:2015 — Medical device software — Software life cycle processes (UK designated standard under SI 2002/618)
IEC 60601-1:2005+AMD1:2012 Clause 14 — Requirements for medical electrical equipment with programmable electrical medical systems (PEMS)
ISO 14971:2019 — Medical devices — Application of risk management to medical devices
MHRA Guidance: Software and artificial intelligence as a medical device (gov.uk)
DCB0129 / DCB0160 — Clinical Risk Management standards (NHS Digital, applicable to health IT in NHS settings)		 Both IEC 62304 and YY/T 0664-2020 are substantively aligned, providing good documentation portability. Key gaps: (1) UK technical documentation must reference IEC 62304 as a UK designated standard under SI 2002/618 and link software safety evidence to UK Essential Requirements — NMPA dossier references to YY/T 0664 alone are insufficient; (2) MHRA SaMD guidance introduces UK-specific classification criteria that may differ from NMPA SaMD guidance; (3) NHS-deployed devices must comply with DCB0129/DCB0160 clinical safety standards — no equivalent obligation exists in China; (4) Cybersecurity expectations for medical device software are addressed in MHRA guidance and expected to be formalised in the new UK MDR framework, potentially requiring a software bill of materials (SBOM) and cyber-risk assessment; NMPA cybersecurity guidelines exist but differ in scope.[INFORMATIONAL ONLY] Existing IEC 62304 / YY/T 0664-2020 documentation provides a strong foundation for UK compliance. Update technical file references to cite IEC 62304 as a UK designated standard under SI 2002/618 and link to UK Essential Requirements. Separately assess MHRA SaMD classification and DCB0129/0160 obligations if the device is intended for NHS deployment. This is informational; seek qualified UK regulatory counsel before submission. MHRA / UK Government (gov.uk)2026-06-12 · unverified
UK Responsible Person (UKRP) and MHRA Device Registration For domestic Chinese market registration, there is no direct equivalent to a UK Responsible Person. Foreign manufacturers registering devices in China under NMPA may appoint a China agent (境内代理人) — a Chinese legal entity — to act on their behalf in the NMPA registration process, handle correspondence, and assume certain regulatory obligations. The China agent's details are listed on the NMPA registration certificate. For Chinese manufacturers exporting to the UK, there is no NMPA-mandated obligation to appoint a foreign representative for the UK market; this is solely a UK requirement.NMPA Order No. 47 (2021) — Administrative Measures for Medical Device Registration and Filing (China agent provisions for foreign manufacturers registering in China) Under the UK Medical Devices Regulations 2002 (SI 2002/618), as amended, any manufacturer established outside the United Kingdom must appoint a UK Responsible Person (UKRP) before registering a medical device with MHRA and placing it on the Great Britain market. The UKRP must be a legal entity or individual established in the United Kingdom (England, Scotland, or Wales for Great Britain market purposes). The UKRP's responsibilities include: registering the device on the MHRA Device Online Registration System (DORS); acting as the UK point of contact for MHRA; ensuring the device's technical documentation, Declaration of Conformity, and post-market obligations meet UK regulatory requirements; and reporting serious adverse events (SAEs) and field safety corrective actions (FSCAs) to MHRA. The UKRP's name, registered address, and contact details must appear on the device label or in accompanying documents. MHRA registration (DORS) is mandatory for all Class I, IIa, IIb, and III devices before placing on the GB market, regardless of UKCA or CE transitional route. Registration must be renewed annually.UK Medical Devices Regulations 2002 (SI 2002/618) as amended — Regulation 19A (UK Responsible Person), Regulation 19B (registration obligations)
MHRA Guidance: UK Responsible Person for medical devices (gov.uk)
MHRA Device Online Registration System (DORS): https://www.gov.uk/guidance/register-as-a-medical-device-manufacturer
Medical Devices (Amendment) (Great Britain) Regulations 2024		 The UKRP obligation is a hard requirement with no equivalent in Chinese export regulations. Key gaps: (1) Chinese manufacturers must identify and contract a UK-established legal entity as UKRP before any device can be placed on the GB market — this is a legal prerequisite, not optional; (2) The UKRP must be registered on DORS and their details must appear on device labels — this requires label changes for devices transitioning from CN-only to UK market; (3) Annual MHRA registration renewal is mandatory regardless of device sales volume; (4) The UKRP bears direct legal responsibility for regulatory reporting obligations in the UK — manufacturers must carefully define contractual responsibilities with their UKRP; (5) No equivalent MHRA DORS registration obligation exists for NMPA-registered devices in China.[INFORMATIONAL ONLY] Appointing a UK Responsible Person and completing MHRA DORS registration are non-negotiable prerequisites for GB market access — they must be in place before any device is placed on the market. Budget for UKRP service fees (typically annual contract) and ensure the UKRP's details are incorporated into labelling. This is informational; seek qualified UK regulatory counsel. MHRA / UK Government (gov.uk)2026-06-12 · unverified

E-E-A-T

Named editorial review

Pending named reviewer

Official regulator, standards body, notified body, customs, or primary legal source preferred. Local PDFs are not accepted.

Editorial controls

Rows must include publisher, official URL, access date, verification flag, and last_verified before human_reviewed can be true.

SOURCES

Official-source register.